Supplementary Material for: Lung adenocarcinoma size decrease after SARS-CoV-2 vaccination during long-term pembrolizumab treatment: A case report

A man in his late 40s was diagnosed with clinical stage IVB lung adenocarcinoma with a PD-L1 tumor proportion score of 100% and high tumor mutational burden. A partial response was achieved after administration of pembrolizumab. The patient received two doses of a SARS-CoV-2 vaccine (BNT162b2) after 59 courses, and a chest CT revealed consolidation in the peri-tumoral area, which subsequently disappeared, and the tumor continued to shrink in the next four months. This case provides indirect evidence for the persistence of cancer immunity during long-term treatment with immune checkpoint inhibitors and the potential for further activation.